JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $110,000 | -6.8% | 2,407 | -8.6% | 0.00% | 0.0% |
| Q3 2017 | $118,000 | +20.4% | 2,633 | -19.9% | 0.00% | 0.0% |
| Q2 2017 | $98,000 | +25.6% | 3,288 | -6.4% | 0.00% | 0.0% |
| Q1 2017 | $78,000 | +20.0% | 3,514 | +1.4% | 0.00% | +100.0% |
| Q4 2016 | $65,000 | -37.5% | 3,465 | 0.0% | 0.00% | -50.0% |
| Q3 2016 | $104,000 | +1055.6% | 3,465 | +1433.2% | 0.00% | – |
| Q2 2016 | $9,000 | 0.0% | 226 | 0.0% | 0.00% | – |
| Q1 2016 | $9,000 | -10.0% | 226 | 0.0% | 0.00% | – |
| Q4 2015 | $10,000 | +11.1% | 226 | 0.0% | 0.00% | – |
| Q3 2015 | $9,000 | -25.0% | 226 | 0.0% | 0.00% | – |
| Q2 2015 | $12,000 | – | 226 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $83,627,000 | 94.97% |
| Crestline Management, LP | 9,348,799 | $419,387,000 | 58.30% |
| Omega Fund Management, LLC | 1,074,612 | $48,207,000 | 27.27% |
| PECONIC PARTNERS LLC | 570,000 | $25,570,000 | 4.12% |
| SIB LLC | 100,000 | $4,486,000 | 3.22% |
| Cormorant Asset Management, LP | 375,000 | $16,823,000 | 2.97% |
| BB BIOTECH AG | 2,055,000 | $92,187,000 | 2.55% |
| Clarius Group, LLC | 117,896 | $5,289,000 | 2.23% |
| Monashee Investment Management LLC | 122,000 | $5,473,000 | 2.07% |
| Iguana Healthcare Management, LLC | 150,000 | $6,730,000 | 1.86% |